To investigate the mechanism by which pulsatile administration of gonadotrophin-releasing hormone (GnRH) modifies secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), we studied three groups of five women who had been ovariectomized for non-malignant gynaecological conditions at least 6 months previously, none of whom had received substitutional hormone therapy. Before and after 15 day treatment with subcutaneous pulsatile GnRH (one 20 µg dose every 90 min in group A, one 10 µg dose every 90 min in group B and one 20 µg dose every 120 min in group C), pulsatile secretion of LH and FSH was characterized by determining these hormones in 4 ml blood samples taken every 10 min for 8 h (9.00 a.m. to 5.00 p.m.). For both LH and FSH, mean serum concentration and pulse amplitude were lower after GnRH treatment than before (and in the case of LH the decrease depended upon both the size and frequency of exogenous GnRH pulses) but in no group was there a significant change in LH or FSH pulse frequency. We conclude that exogenous pulsatile GnRH probably acts by partially desensitizing the pituitary rather than by depressing endogenous GnRH secretion. Such partial desensitization would explain reports that exogenous pulsatile GnRH improves ovulation by women with polycystic ovary syndrome.
Introduction
The amplitude and frequency of the gonadotrophin pulses secreted by the pituitary of women of fertile age depend on the phase of the menstrual cycle (Filicori et al., 1986) . Secretion is stimulated by pulses of gonadotrophin-releasing hormone (GnRH) that are emitted by the hypothalamus under the control of the 'GnRH pulse generator' and other signals relayed via diverse neuron nuclei (Leranth et al., 1992) , and is regulated by feedback from the gonads.
We have previously reported that pulsatile subcutaneous administration of GnRH induces ovulation more rapidly in women with low or zero gonadotrophin levels due to hypogonadotrophic hypogonadism of hypothalamic origin, than in women with normal gonadotrophin levels receiving GnRH for oligomenorrhoea (Graña, 1997) . We interpreted this finding as showing that exogenous GnRH requires a certain time to prevail over the action of endogenous GnRH. Two suggestions have been put forward as to the mechanism by which exogenous GnRH prevails over the endogenous hormone: partial desensitization of the pituitary (Lambalk et al., 1986 (Lambalk et al., , 1987 and depression of secretion of GnRH by the hypothalamus (Lambalk et al., 1991) .
To clarify the mechanism of action of exogenous pulsatile GnRH, we have now studied the effects of three different administration regimens on secretion of follicle stimulating hormone (FSH) and luteinizing hormone (LH) in ovariectomized women.
Material and methods

Subjects
We studied 15 women aged 44-55 years who had been ovariectomized on account of non-malignant gynaecological conditions at least 6 months previously (seven for uterine leiomyoma, four for ovarian endometriosis and four for ovarian cystadenoma). None had received substitutional hormone treatment, and none had taken psychotropic, anti-epileptic or neuroleptic drugs in the 3 months prior to this study. All volunteered to take part in the study after being duly informed of its nature, and gave written consent. Before their inclusion, determination of FSH, LH, oestradiol, triiodothyronine (T3), thyroxine (T4) and thyroid-stimulating hormone (TSH) confirmed surgical menopause (FSH Ͼ40 IU/l, oestradiol Ͻ50 pg/ml) and ruled out thyroid dysfunction and other alterations, and standard haematological and biochemical parameters were found to be normal.
Experimental protocol
The subjects were assigned to three groups: the first five to group A, the second five to group B and the third five to group C. In each subject, pulsatile secretion of LH and FSH was characterized before (day 0) and after (day 16) a group-specific 15 day treatment with subcutaneous pulsatile GnRH (Luforan ® 500, Serono, Madrid, Spain), administered by means of a Zyklomat Pulse infusion pump (Ferring, Kiel, Germany) . Group A subjects received one 20 µg dose every 90 min, group B subjects a 10 µg dose every 90 min and group C subjects a 20 µg dose every 120 min. Characterization of LH and FSH secretion was based on their determination in 4 ml blood samples taken every 10 min over an 8 h period (09.00-17.00 h), during which time the subject remained seated or supine and took a continental breakfast and a light lunch, together totalling approximately 2000 calories. The last GnRH pulse was administered 1 min before the third blood sample of the post-treatment characterization session was taken.
Determination of hormones
Blood samples were centrifuged immediately and the resulting sera were stored at -20°C pending analysis. FSH, LH and oestradiol were determined in triplicate (in each case with the three subsamples in a single run) using an ACS-180 Plus automatic analyser (Chiron Diagnostics, Medfield, MA, USA) and reagents from the same supplier; FSH and LH were determined by sandwich immunoluminescence assays, and oestradiol by a competitive immunoluminescence assay using monoclonal antibody against position 6 of the oestradiol molecule. The FSH method, calibrated with WHO 2nd International
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Reference Preparation (1980) (NIBSC 78/549), had a detection limit of 0.03 IU/l and conditional coefficients of variation (CVs) of 6.81% at 5.9 IU/l and 6.35% at 64.7 IU/l. The LH method, calibrated with WHO 2nd International Reference Preparation (1988) (NIBSC 80/ 552), had a detection limit of 0.09 IU/l and conditional CVs of 3.86% at 5.5 IU/l and 4.14% at 36.1 IU/l.
Pulse detection
LH and FSH pulses in serum were detected by a non-parametric statistical method (Lado-Abeal et al., 1991) that in validatory trials with simulated LH series had achieved a sensitivity and positive accuracy (Urban et al., 1989) of 0.88 and 1.00 respectively, with a sum of 1.88 similar to that reported for the cluster method (Urban et al., 1988) . The parameters calculated were pulse amplitude, interpulse interval, the number of pulses in the 8 h session, and mean hormone level over the 8 h period.
Expression of results and statistical analysis
Pulse amplitude, interpulse interval and mean concentration results are expressed in the tables below as means Ϯ SD for each group and session, with medians in parentheses. The statistical significance of differences among groups was estimated with the Kruskal-Wallis test; when significant differences were detected, pairwise comparisons were effected using the Mann-Whitney test. Within-group differences between pre-and post-treatment values were assessed with the Wilcoxon matching pairs test. Figure 1 shows how serum LH and FSH concentrations varied during the pre-treatment and post-treatment studies in three subjects (one from each group).
Results
Mean serum LH concentration
During the first (pre-treatment) evaluation, there were no statistically significant differences among the mean serum LH concentrations in the three subject groups (Table I ). The mean levels in the post-treatment session were decreased. The fall was significantly larger for group A than for groups B and C, in keeping with which the post-treatment value for group A was significantly lower than those for groups B and C, which did not differ significantly from each other.
LH pulses
Pre-treatment, there were no significant differences among the three groups as regards LH pulse amplitude (Table II) . The post-treatment values were significantly lower than the pretreatment values in all three groups, and were significantly lower in group A than in group B or group C. Both pre-and post-treatment, the interval between LH pulse peaks was significantly shorter in group A than in group C, but in no group was there a significant difference between pre-and posttreatment values (Table II) .
Mean serum FSH concentration
In each group, mean serum FSH concentration was significantly lower after GnRH treatment than before, but neither before nor after treatment were there significant differences among the three groups (Table III) .
FSH pulses
Pre-treatment FSH pulse amplitude was significantly smaller in group C than in the other groups, but the three groups did not differ significantly in this respect after treatment (Table IV) . Post-treatment FSH pulse amplitude was only significantly different from the pre-treatment value in the groups receiving 20 µg GnRH pulses. Before GnRH treatment, the interval between FSH pulse peaks was significantly shorter in group A than in group B or group C. For no group was the posttreatment FSH interpulse interval significantly different from the pre-treatment value, nor were there any significant differences in post-treatment FSH interpulse interval among the three groups.
Discussion
Menopausal and ovariectomized women are ideal subjects for the study of pituitary gonadotrophin secretion and its modification because of their large FSH and LH pulses and 528 the absence of ovarian feedback to which these large pulse amplitudes are due.
In this study, 15 day subcutaneous pulsatile administration of GnRH to ovariectomized women was followed by a fall in their mean serum LH concentrations and LH pulse amplitudes to values typical of the medium-late follicular phase (LadoAbeal et al., 1991) . The extent of the reduction depended in both cases on both the size and the frequency of the GnRH pulses, the most effective of the three regimens used being one 20 µg dose every 90 min. These findings agree with those of other authors (Uemura et al., 1992; Scheele et al., 1996) .
The GnRH treatment was also followed by a fall in mean serum FSH concentrations, but the percentage reduction was less than for LH and did not differ significantly among groups (which is compatible with the possibility of a mechanism that is independent of GnRH pulse size and frequency). FSH pulse amplitude was significantly reduced by administering GnRH at a level of 20 µg per pulse, regardless of pulse frequency, but not by 10 µg pulses.
The intervals between gonadotrophin pulses were not significantly altered by the GnRH treatment in any group. This suggests that the GnRH-induced reduction in gonadotrophin levels is less likely to have been due to suppression of hypothalamic emission of GnRH (one of the mechanisms mooted by Lambalk et al., 1991) than to partial desensitization of the pituitary by GnRH, a well-documented effect of exogenous GnRH (Lambalk et al., 1986; Conn and Crowley, 1991) .
The differences between the responses of LH secretion and FSH secretion to exogenous pulsatile GnRH suggest that synthesis and/or release of FSH may not be so dependent on GnRH as in the case of LH, an observation previously made by Genazzani and co-workers (Genazzani et al., 1994 (Genazzani et al., , 1996 . This would explain why GnRH analogues reduce LH and FSH levels to markedly different extents, inhibiting LH secretion almost completely but reducing serum FSH only to medium follicular phase levels (Broekmans et al., 1993) .
There is controversy as to whether the use of GnRH analogues is always advantageous in reproductive medicine (Kingsland et al., 1992) or guarantees a reduction in the incidence of serious complications of gonadotrophin treatment such as multiple pregnancy or ovarian hyperstimulation syndrome (OHS) (Ron-El et al., 1991) . It has been suggested that GnRH analogues may even favour the development of OHS, especially in women with polycystic ovary syndrome (PCOS) (Navot et al., 1992) , and that they may harm the oocyte (Pellicer et al., 1992; Testart et al., 1993) . PCOS involves high serum LH concentrations (Burger et al., 1989) due to both the frequency and amplitude of LH pulses being increased by a hyperactive hypothalamo-pituitary axis (Waldstreicher et al., 1986; Kazer et al., 1987) , but it seems plausible that to treat PCOS and other anovulatory conditions involving high LH levels, it may suffice to depress pituitary activity partially rather than entirely (Monroe et al., 1986; Filicori et al., 1993) . The partial suppression of LH and FSH levels in the present study of ovariectomized women suggests that this can be achieved by pulsatile GnRH treatment, and this notion seems to be in consonance with reports that the ovulation of women with PCOS is improved by pulsatile administration of GnRH both when this treatment is given following administration of GnRH analogues (Filicori et al., 1991) and also when it is given in successive menstrual cycles (Corenthal et al., 1994) . We postulate that in both cases pulsatile GnRH causes partial suppression of gonadotrophin secretion: when given following GnRH analogues, this results in its being associated with an immediate rise in gonadotrophin levels (given the total suppression brought about by the analogues), and when given in successive cycles it brings about a fall in gonadotrophin levels (an effect that only becomes manifest in the second cycle). It is therefore possible that the best GnRH 'analogue' is exogenous GnRH, in the sense that GnRH achieves the desired effects without completely suppressing LH secretion and without giving rise to climacteric symptoms.
The dependence of follicle maturation on the presence of low levels of LH as well as FSH has recently been stressed by Hillier (1996) , who stated that in women with WHO Type 1 infertility, the response to pure FSH will depend on simultaneous administration of LH. The induction of pituitary production of both gonadotrophins by pulsatile exogenous GnRH may be a more natural alternative to direct administration of gonadotrophins.
To sum up, in this work we found that 15 day subcutaneous pulsatile administration of GnRH to ovariectomized women brought about a significant dose-and frequency-dependent reduction in the mean serum concentration and pulse amplitude of LH, together with a reduction in mean FSH levels that, in this study, did not depend on dose or frequency to a statistically significant extent; the intervals between LH or FSH pulses were not altered by the GnRH treatment. We conclude that pulsatile administration of GnRH at an appropriate pulse frequency probably reduces gonadotrophin levels by decreasing the sensitivity of the pituitary to GnRH rather than by depressing hypothalamic GnRH emission, and reason that this effect may prove useful for hormonal control in reproductive medicine.
